Live biotherapeutics market seen reaching $182.5B by 2030

The live biotherapeutics market is projected to grow from $92.31 billion in 2025 to $182.52 billion by 2030, fueled by microbiome science, gastrointestinal disease prevalence and broader use of targeted non-antibiotic therapies. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Live biotherapeutics are moving from niche microbiome research into a larger drug-development market. - The category could reshape treatment options for gastrointestinal disease, inflammatory bowel disease and other chronic conditions. - A larger market may accelerate clinical trials, regulatory approvals and investment in microbiome-based medicines.

What happened: - The Business Research Company published its Live Biotherapeutics Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report estimates the global live biotherapeutics market at $92.31 billion in 2025. - The market is projected to reach $105.62 billion in 2026, implying 14.4% growth. - The market is forecast to climb to $182.52 billion by 2030, with a 14.7% CAGR from 2026. - The report says North America held the largest market share in 2025. - The report says Asia-Pacific will be the fastest-growing region over the forecast period. - Download a free sample of the report. - View the full market report.

The details: - Live biotherapeutics are medicinal products containing living microorganisms such as bacteria or yeasts. - These products are designed to prevent, treat or manage human disease. - The products work by interacting with a person’s microbiota or physiological systems. - The report says they are developed under pharmaceutical guidelines for safety, quality and effectiveness. - Historical growth has been driven by rising gastrointestinal and metabolic disease rates, more clinical use of probiotics, early microbiome research, greater awareness of gut health and limited availability of targeted biological treatments. - Future growth is expected to come from precision microbiome engineering, more regulatory approvals, higher investment in microbiome-based drug development, broader use of personalized medicine and demand for non-antibiotic targeted therapies. - Anticipated trends include microbiome-based treatments in hospital protocols, more personalized microbiome modulation, better standardization and regulatory alignment, more trials for engineered microbial therapies and greater demand for antibiotic alternatives in chronic disease. - The report identifies gastrointestinal disorders and inflammatory bowel disease as a major growth driver. - Crohn's & Colitis Australia projected in February 2025 that IBD cases in Australia will rise from 20,511,881 in 2023 to 23,067,771 by 2030. - The 2026 report edition adds market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables.

Between the lines: - The forecast suggests live biotherapeutics are becoming more commercially viable as regulators and drug developers gain more evidence on microbiome-based therapy. - Strong projected demand for non-antibiotic treatments points to persistent pressure on conventional therapies in chronic inflammatory and digestive disease markets. - The regional split suggests mature research ecosystems still lead the category, but faster growth in Asia-Pacific may widen the geographic base of development and commercialization.

What's next: - More clinical trials for engineered microbial therapies are expected as the category matures. - Additional regulatory approvals could help normalize live biotherapeutics inside standard treatment pathways. - Hospitals may increasingly integrate microbiome-based therapies into protocols if evidence and standardization improve. - Broader investment in personalized medicine could push companies toward more targeted microbiome modulation products.

The bottom line: - Live biotherapeutics are emerging as a fast-growing treatment class with a projected near-doubling of market value by 2030 and broad momentum from microbiome science, chronic disease burden and demand for alternatives to antibiotics.